Ebpay生命医药出版社

Ebpay生命

100566

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





视频

Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction

 

Authors Dell SJ, Gaster RN, Barbarino SC, Cunningham DN

Received 20 December 2016

Accepted for publication 9 February 2017

Published 2 May 2017 Volume 2017:11 Pages 817—827

DOI http://doi.org/10.2147/OPTH.S130706

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Purpose: The aim of this study was to estimate the efficacy of intense pulsed light (IPL), followed by meibomian gland expression (MGX), for reducing the number and severity of signs and symptoms of dry eye disease (DED) secondary to meibomian gland dysfunction (MGD).
Patients and methods:
 In a prospective study conducted in two sites, 40 subjects (80 eyes) with moderate to severe MGD were enrolled. Major inclusion criteria consisted of at least two of the following measures being compatible with DED in both eyes: tear breakup time (TBUT), meibomian gland score (MGS), corneal fluorescein staining (CFS), Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and tear film osmolarity (TFO). Enrolled patients underwent four treatment sessions, 3 weeks apart. Each treatment included the administration of 10–15 pulses of IPL on the cheeks and nose, followed by MGX of the upper and lower eyelids. TBUT, MGS, CFS, SPEED, TFO, and lipid layer thickness (LLT) were measured at baseline (BL) and at 9, 12, and 15 weeks after BL.

Results: Due to different staining methods used for TBUT measurements, TBUT and CFS were analyzed separately for each site. From BL to the final follow-up, the number of signs compatible with DED decreased from 3.3±0.1 to 1.4±0.1. TBUT improved by +93% (n=38; <0.0001) and +425% (n=42; <0.0001) for sites 1 and 2, respectively. SPEED, MGS, and CFS improved by -55% (n=80; <0.0001), -36% (n=80; <0.0001), and -58% (n=38; <0.0001), respectively. In 20 eyes with abnormally elevated TFO at BL, TFO improved by -7% (n=20; <0.005). LLT did not change (n=38; =0.88).
Conclusion: 
In subjects with moderate to severe MGD, IPL combined with MGX reduced the number and severity of symptoms and signs of DED. Except for LLT, all examined outcome measures significantly improved after 15 weeks. These results support the efficacy of IPL + MGX in relieving both signs and symptoms of DED secondary to MGD.
Keywords: dry eye, meibomian gland dysfunction, intense pulsed light


摘要视频链接:Evaluation of IPLand MGX on relieving DED signs and symptoms






Download Article[PDF]